April 2026
Serotonin
What April 2026's 5 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in April 2026 focused on developing novel serotonergic compounds and understanding psychedelic mechanisms. Studies introduced 2-halogenated tryptamines as potential next-generation therapeutics with reduced psychoactivity and cardiotoxicity, and identified a conserved glucocorticoid-responsive gene signature induced by psilocybin across multiple brain regions in rats. However, evidence for clinical efficacy in conditions like Alzheimer's disease remains preclinical and hypothesis-generating, and the field is still limited by small sample sizes and lack of human trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders. 2026 | theoretical | Supports | This study proposes novel indoline derivatives as 5-HT2A agonists for treating psychosis and CNS disorders. | |
| Serotonergic Polypharmacology of 2-Halogenated Tryptamines. 2026 | preclinical | Supports | 2-halogenated tryptamines showed reduced 5-HT2A/5-HT2B activity, preserved 5-HT6 agonism, and improved stress-induced affective measures in mice without inducing psychedelic effects. | |
| Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat. 2026 | preclinical | 24 | Supports | Psilocybin induced a conserved glucocorticoid-responsive gene signature (e.g., Nfkbia, Sgk1 upregulation) across five 5-HT2A receptor-rich brain regions in rats. |
| Dorsal Raphe Revisited: A Systems Neuroscience Lens on Psychedelic Drug Action 2026 | review | Unclear | This review traces the history of LSD research on the dorsal raphe, concluding that early hypotheses about serotonergic neurons driving hallucinogenic effects have shifted toward a systems neuroscience perspective. | |
| Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes. 2026 | theoretical | Supports | This hypothesis-generating model suggests that classic hallucinogens may restore mitochondrial integrity in Alzheimer's disease via 5-HT2A and sigma-1 receptors, but evidence remains preclinical. |
This study proposes novel indoline derivatives as 5-HT2A agonists for treating psychosis and CNS disorders.
theoretical
2-halogenated tryptamines showed reduced 5-HT2A/5-HT2B activity, preserved 5-HT6 agonism, and improved stress-induced affective measures in mice without inducing psychedelic effects.
preclinical
Psilocybin induced a conserved glucocorticoid-responsive gene signature (e.g., Nfkbia, Sgk1 upregulation) across five 5-HT2A receptor-rich brain regions in rats.
preclinical Sample size: 24
This review traces the history of LSD research on the dorsal raphe, concluding that early hypotheses about serotonergic neurons driving hallucinogenic effects have shifted toward a systems neuroscience perspective.
review
This hypothesis-generating model suggests that classic hallucinogens may restore mitochondrial integrity in Alzheimer's disease via 5-HT2A and sigma-1 receptors, but evidence remains preclinical.
theoretical
Points of agreement
- All studies implicate the 5-HT2A receptor as a key target for serotonergic psychedelics and related compounds.
- Preclinical evidence consistently supports the therapeutic potential of serotonergic compounds for psychiatric and neurodegenerative conditions.
- The studies agree that reducing 5-HT2A activity can mitigate psychoactive effects while preserving therapeutic benefits.
Conflicts
- No direct conflicts are reported; however, the review (article 28034) notes that early hypotheses about serotonergic neurons driving hallucinogenic effects have been revised, contrasting with earlier interpretations.
Gaps
- No human clinical trials are included; all evidence is preclinical or theoretical.
- Durability of effects and long-term safety are not addressed.
- The studies lack diverse populations and do not examine dose-response relationships in humans.
- The translational feasibility and neuropsychiatric safety of these compounds remain unstudied in clinical settings.